Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

NCT02184351 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02184351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02184351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2001
Completion date
Not reported
Enrollment
187 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

candidiasis, oral